Medication info
Janumax Tablet 100 Milligrams (Sitagliptin Phosphate Monohydrate)

Janumax Tablet 100 Milligrams (Sitagliptin Phosphate Monohydrate)

Prescription medicationTablet
Ingredient · strength
Sitagliptin Phosphate Hydrate›128.5mg / 1 tablet
Manufacturer / importer
Samik Pharmaceutical Co., Ltd.
Appearance
Beige, round, biconvex film-coated tablet
Packaging
Bottle - 30 tablets/bottle, Bottle - 90 tablets/bottle
Approval status
Active

MFDS item code 202005113 · Approved 2020.07.15 · Insurance code 644004510

Summary

Main use
Improvement of blood glucose control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
This medicine is administered at 100 mg once daily, either as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dose adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Samik Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in type 2 diabetes mellitus

View approved original text

This medication is used in combination with diet and exercise to improve blood sugar control in patients with type 2 diabetes. It can be administered alone or in conjunction with other medications and effectively aids in blood sugar management.

Dosage and Administration

Adult dosage

This medicine is administered at 100 mg once daily, either as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dose adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Precautions

This medication can cause severe allergic reactions during use; if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur, discontinue use immediately and consult a doctor. Inflammation of the pancreas may occur while taking this medication; if symptoms such as severe abdominal pain, vomiting, or nausea develop, inform medical personnel immediately. Patients with type 1 diabetes or diabetic ketoacidosis should not take this medication, and it should not be used if there is an allergy to this drug or its ingredients. Patients with reduced kidney function require dosage adjustments; thus, kidney function tests should be performed before use and the medication should be taken following a doctor's instructions. There is a risk of hypoglycemia when taking this medication, so if used in combination with insulin or sulfonylureas, blood sugar should be monitored frequently, and measures should be taken if hypoglycemic symptoms occur. If severe joint pain or skin blistering occurs, discontinue the medication immediately and consult a specialist. This medication is not recommended for pregnant or nursing women, and its safety and efficacy in children under 18 years of age have not been established. Elderly patients may experience reduced kidney function, thus kidney function should be assessed before starting this medication, and periodic testing during treatment is necessary. In the case of overdose, gastrointestinal decontamination and clinical monitoring including electrocardiography should be conducted, and if necessary, some drug elimination can be achieved through hemodialysis. This medication has a low potential for drug interactions when used in combination with other hypoglycemic agents; however, caution is required when used with specific drugs, and consultation with a doctor or pharmacist is advised.

Side effects

  • Severe allergic reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • exfoliative skin disease
  • acute pancreatitis
  • hypoglycemia
  • upper respiratory infection
  • nasopharyngitis
  • headache
Show 31 more
  • diarrhea
  • abdominal pain
  • nausea
  • peripheral edema
  • dyspepsia
  • dizziness
  • increased liver enzymes
  • acute renal failure
  • constipation
  • vomiting
  • arthralgia with severity and disability
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • pneumonia
  • diabetes complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • increased serum triglycerides
  • increased low-density lipoprotein
  • hyperglycemia
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent intrusion of air or moisture. It is recommended to keep it at room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Beige, round, biconvex film-coated tablet

Package unit

Bottle - 30 tablets/bottle, Bottle - 90 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.